trending Market Intelligence /marketintelligence/en/news-insights/trending/Vp8YCD-OBauKzIQ-_EtYCQ2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

US FDA approves Endo's application for low blood pressure injection

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


US FDA approves Endo's application for low blood pressure injection

Endo International PLC's operating company Par Pharmaceutical received final approval from the U.S. FDA for its new drug application for ephedrine sulfate injection.

The drug is a parenterally administered pressor agent to address hypotension, which is low blood pressure, in surgical settings.

U.S. sales of ephedrine sulfate injection products were about $177 million for the 12 months ended Nov. 30, 2016, according to IMS Health data.

Par Pharmaceutical anticipates shipping of the product to begin in February.